A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
Artios, Synnovation and Novartis show mere glimmers of activity.
